ALB and Hypocalcemia: Upacicalcet's interdialytic half-life of plasma and removal rate in a HD session ranged between 65 and 122 hours and 79% and 100% in HD patients, respectively.20 Thus, the plasma upacicalcet concentration plateaus after repeated 1-week dosing.20 The pharmacokinetic properties of upacicalcet differ from those of etelcalcetide, which forms a serum albumin peptide conjugate and accumulates in the plasma.34 A careful dosing titration regimen of upacicalcet may lower serum iPTH concentrations, avoiding hypocalcemia associated with excessive drug effects.